352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Bristow Group reported second quarter 2024 total revenues of $359.7 million and net income of $28.2 million, or $0.96 per diluted share, up from $337.1 million and $6.6 million, or $0.23 per diluted share, in the first quarter. The company raised its 2024 Adjusted EBITDA outlook to $210 million to $230 million from $190 million to $220 million, and its 2025 outlook to $230 million to $260 million from $210 million to $245 million.
Q2 2024 total revenues were $359.7 million, compared with $337.1 million in Q1 2024.
Q2 2024 net income was $28.2 million, or $0.96 per diluted share, compared with $6.6 million, or $0.23 per diluted share, in Q1 2024.
Adjusted EBITDA excluding asset dispositions and foreign exchange was $71.3 million, compared with $47.5 million in Q1 2024.
As of June 30, 2024, total liquidity was $246.4 million, including $178.6 million of unrestricted cash.
Ormat Technologies reported second-quarter 2024 total revenues of $213.0 million, up 9.3% from a year earlier, and operating income up 45%. GAAP net income attributable to stockholders fell 8.1% to $22.2 million, and diluted EPS dropped to $0.37 from $0.40, while adjusted EBITDA rose 25% to $126.1 million and the company raised its full-year EBITDA guidance range.
Total revenues $213.0 million vs. $194.8 million in Q2 2023; Electricity, Product and Energy Storage segments all grew.
Net income attributable to stockholders $22.2 million vs. $24.2 million; diluted EPS $0.37 vs. $0.40, including about $2.0 million in after-tax write-offs.
Adjusted EBITDA $126.1 million, up 25.0%; adjusted diluted EPS $0.40, flat year over year.
2024 guidance: total revenues $875 million to $910 million; adjusted EBITDA $520 million to $550 million. Quarterly dividend of $0.12 per share declared, payable September 3, 2024.
Veracyte reported second-quarter 2024 total revenue of $114.4 million, up 27% from $90.3 million a year earlier, and swung to net income of $5.7 million from a net loss of $8.4 million. The company raised its full-year 2024 total revenue guidance to $432 million to $438 million from $402 million to $410 million, which is a positive signal for shareholders.
Q2 2024 total revenue was $114.4 million, up 27% from $90.3 million in Q2 2023; testing revenue rose 31% to $107.0 million.
Net income was $5.7 million, or $0.07 per diluted share, versus a net loss of $8.4 million, or $(0.12) per share, in Q2 2023.
Adjusted EBITDA was $24.0 million, or 21% of revenue, compared with $11.0 million, or 12% of revenue, a year earlier.
Full-year 2024 total revenue guidance rose to $432 million to $438 million; year-end cash guidance rose to $260 million to $270 million.
DaVita reported second-quarter 2024 revenue of $3.187 billion, up from $3.000 billion a year earlier, and diluted EPS of $2.50 versus $1.91. The company raised its 2024 adjusted diluted EPS guidance to $9.25-$10.05 from $9.00-$9.80, though the filing notes that the change reflects a new presentation that no longer excludes about $60 million in center closure costs.
Q2 2024 total revenues were $3.187 billion versus $3.000 billion in Q2 2023; operating income was $506 million versus $405 million.
Diluted EPS was $2.50 versus $1.91 a year earlier; adjusted diluted EPS was $2.59 versus $2.26 in the first quarter of 2024.
Current 2024 adjusted diluted EPS guidance is $9.25 to $10.05, compared with prior guidance of $9.00 to $9.80 given as of May 2, 2024.
During Q2 2024 the company repurchased 2.7 million shares for $376 million.
Gulfport reported a second-quarter 2024 net loss of $26.2 million, compared with net income of $93.7 million a year earlier, as total revenues fell to $181.1 million from $304.7 million. The company kept its full-year capital guidance unchanged and narrowed its 2024 production forecast, but reported profit and revenue declined sharply for shareholders.
Q2 2024 net loss of $26.2 million vs. net income of $93.7 million in Q2 2023; total revenues $181.1 million vs. $304.7 million
Diluted loss of $1.51 per share vs. diluted earnings of $4.18 per share a year earlier
2024 production guidance narrowed to 1,055-1,070 MMcfe per day; capital expenditure guidance unchanged, with over $25 million in expected savings
Repurchased about $25.0 million of common stock in Q2 2024; about $188.8 million of repurchase capacity remained as of July 29, 2024
MasterBrand reported second-quarter 2024 results on August 6, 2024, with net sales down 2.7% to $676.5 million and net income down 11.5% to $45.3 million from a year earlier. The company raised its full-year 2024 outlook after closing its $520 million net cash acquisition of Supreme Cabinetry Brands, but the filing says organic net sales are expected to decline by a low single-digit percentage.
Diluted EPS was $0.35 versus $0.39 a year earlier; adjusted diluted EPS was $0.45 versus $0.44, with the adjusted measure now excluding amortization.
2024 outlook: adjusted EBITDA of $385 million to $405 million and adjusted diluted EPS of $1.50 to $1.62.
Supreme Cabinetry Brands closed after the quarter ended, for a net cash payment of $520 million.
Operating cash flow was $96.1 million for the 26 weeks ended June 30, 2024, versus $194.0 million a year earlier; free cash flow was $77.8 million.
Exelixis reported second quarter 2024 total revenues of $637.2 million, up from $469.8 million a year earlier, and GAAP diluted EPS of $0.77, up from $0.25. The Board also authorized up to $500 million in additional stock repurchases through the end of 2025, and the company updated its full-year 2024 financial guidance.
Q2 2024 total revenues $637.2 million vs. $469.8 million in Q2 2023; net product revenues $437.6 million vs. $409.6 million
GAAP diluted EPS $0.77 vs. $0.25; non-GAAP diluted EPS $0.84 vs. $0.31
Board authorized repurchase of up to $500 million of common stock through the end of 2025; the $450 million 2024 program was completed
2024 total revenues guidance of $1.975 billion to $2.075 billion; FDA accepted cabozantinib sNDA for advanced NET with PDUFA target date of April 3, 2025
Qualys reported second quarter 2024 revenue of $148.7 million, up 8% from a year earlier, and GAAP diluted EPS of $1.17 versus $0.95. The company lowered its full-year 2024 revenue guidance to $597.5 million-$601.5 million from $601.5 million-$608.5 million, while raising its full-year EPS guidance, which matters to shareholders because the revenue and profit outlooks moved in different directions.
Q2 2024 revenue was $148.7 million, up 8% from $137.2 million; GAAP net income rose 24% to $43.8 million.
Full-year 2024 revenue guidance was cut to $597.5 million-$601.5 million from $601.5 million-$608.5 million.
Full-year 2024 GAAP EPS guidance was raised to $3.85-$4.01 from $3.26-$3.50; non-GAAP EPS guidance was raised to $5.46-$5.62 from $5.06-$5.30.
Q2 operating cash flow fell 3% to $49.8 million from $51.5 million a year earlier.
Astera Labs reported second-quarter 2024 revenue of $76.9 million, up 18% from the first quarter and 619% from a year earlier. GAAP net loss narrowed to $7.5 million, or $0.05 per share, from $93.0 million in the first quarter, which included IPO-related stock-based compensation. The company expects third-quarter revenue of $95 million to $100 million, and IPO lock-up restrictions on officers, directors and major holders are expected to end at the open of trading on August 8, 2024.
Q2 revenue of $76.9 million, up 18% sequentially and 619% year over year
GAAP net loss of $7.5 million, or $0.05 per share, versus a $93.0 million net loss in Q1 2024
Non-GAAP net income of $22.2 million, or $0.13 per diluted share
Q3 2024 revenue outlook of $95 million to $100 million; lock-up restrictions expected to end August 8, 2024
Toast reported second-quarter 2024 results, with revenue of $1,242 million versus $978 million a year earlier and GAAP net income of $14 million compared with a net loss of $(98) million in Q2 2023. The company also raised its full-year 2024 Adjusted EBITDA outlook to $285 million to $305 million from $250 million to $270 million, which matters to shareholders because it signals improved profitability expectations.
Q2 2024 total revenue was $1,242 million, up from $978 million in Q2 2023.
GAAP operating income was $5 million in Q2 2024, compared with an operating loss of $(80) million a year earlier.
Full-year 2024 Adjusted EBITDA guidance was raised to $285 million to $305 million from $250 million to $270 million.
Annualized recurring run-rate (ARR) as of June 30, 2024 was $1.5 billion, up 29% year over year.
Fortinet reported second-quarter 2024 results on August 6, 2024, with total revenue of $1.43 billion, up 10.9% from a year earlier, and GAAP diluted earnings of $0.49 per share, up from $0.33. The company raised its full-year 2024 revenue and non-GAAP operating margin guidance, though product revenue fell and total billings were flat.
Total revenue was $1.43 billion, up 10.9%; service revenue rose 19.8% to $982.4 million while product revenue fell 4.4% to $451.9 million.
GAAP diluted net income per share was $0.49 versus $0.33 a year earlier; non-GAAP diluted EPS was $0.57 versus $0.38.
Non-GAAP operating margin was 35.1%, up from 26.9%, and cash flow from operations was $342.0 million, down from $515.1 million.
For fiscal 2024, Fortinet now expects revenue of $5.800 billion to $5.900 billion and a non-GAAP operating margin of 30.0% to 31.5%.
Sunrun reported second-quarter 2024 results on August 6, 2024. Total revenue fell 11% year over year to $523.9 million, while net income attributable to common stockholders rose to $139.1 million, or $0.55 per diluted share, and the company raised its full-year 2024 storage installation guidance and introduced 2025 cash generation guidance of $350 million to $600 million. A separate filing disclosed that a July 31, 2024 accordion exercise raised commitments under its senior secured credit facility to $2.63 billion.
Total revenue was $523.9 million in Q2 2024, down $66.3 million, or 11%, from Q2 2023.
Net income attributable to common stockholders was $139.1 million, or $0.55 per diluted share, versus $55.5 million, or $0.25 per diluted share, in Q2 2023.
Full-year 2024 storage capacity installed guidance was raised to 1,030 to 1,100 megawatt hours from 800 to 1,000; 2025 cash generation guidance of $350 million to $600 million was introduced.
On July 31, 2024, a subsidiary exercised an accordion under the credit facility, bringing commitments to $2.63 billion.
Adeia reported second-quarter 2024 revenue of $87.4 million, up from $83.2 million a year earlier, and GAAP net income of $8.4 million, versus $1.4 million in the same quarter of 2024's prior year. The company kept its full-year revenue outlook of $380.0 to $420.0 million and raised its GAAP net income outlook to $71.4 to $75.6 million, citing lower operating expenses and interest expense.
Q2 2024 revenue was $87.4 million, up from $83.2 million in Q2 2023 and $83.4 million in Q1 2024.
GAAP diluted EPS was $0.07 versus $0.01 a year earlier; non-GAAP diluted EPS was $0.28 versus $0.26.
Full-year 2024 GAAP net income outlook updated to $71.4 to $75.6 million from $65.4 to $70.7 million; revenue outlook reiterated at $380.0 to $420.0 million.
Term loan repriced, lowering the interest rate by 61 basis points; the outstanding balance was $549.1 million as of June 30, 2024.
Inspire Medical Systems reported second-quarter 2024 revenue of $195.9 million, up 30% from a year earlier, and net income of $9.8 million, compared with a net loss of $12.0 million a year earlier. The company raised its full-year 2024 revenue and diluted EPS guidance and authorized its first share repurchase program, of up to $150.0 million.
Q2 2024 revenue $195.9 million, up 30% from $151.1 million; diluted EPS $0.32 vs. a $0.41 loss a year earlier
Full-year 2024 revenue guidance raised to $788 million-$798 million from $783 million-$793 million
Full-year 2024 diluted EPS guidance raised to $0.60-$0.80 from $0.10-$0.20, excluding any share repurchases
Board authorized repurchase of up to $150.0 million of common stock, the first in company history
Progyny reported second-quarter 2024 revenue of $304.1 million, up 8.8%, with net income of $16.5 million and Adjusted EBITDA of $54.5 million, up 15%. The company said revenue per utilizing member is running below its expectations and revised its second-half outlook, now projecting full-year 2024 revenue of $1.165 billion to $1.20 billion. The board also authorized an additional $100 million share repurchase, which matters to shareholders because the outlook is softer even as profit and buybacks grew.
Q2 2024 revenue was $304.1 million, up 8.8%, and net income was $16.5 million, or $0.17 per diluted share, versus $0.15 a year earlier
Adjusted EBITDA was $54.5 million, up 15%, with an Adjusted EBITDA margin of 17.9%
Full-year 2024 revenue is now projected at $1.165 billion to $1.20 billion; third-quarter revenue is projected at $290.0 million to $303.0 million
On August 5, 2024, the board authorized an additional $100 million of share repurchases, after the company bought 5,593,128 shares for $159.8 million in the second quarter
Cirrus Logic reported fiscal first-quarter 2025 revenue of $374.0 million, up 18% from a year earlier, above the top of its guidance range, driven by stronger-than-expected smartphone shipments. GAAP earnings per share fell to $0.76 from $0.81 in the prior quarter but rose from $0.28 a year earlier. The company guided September-quarter revenue to $490 million to $550 million, which it said is up 39% sequentially at the midpoint.
Q1 FY25 revenue was $374.0 million, up 18% year over year and up 1% from the prior quarter, as reported.
GAAP diluted EPS was $0.76 versus $0.81 in Q4 FY24 and $0.28 in Q1 FY24; non-GAAP diluted EPS was $1.12 versus $1.24 in Q4 FY24.
Q2 FY25 revenue is expected to range from $490 million to $550 million, with GAAP gross margin of 50% to 52%.
Cash and investments ended the quarter at $744.6 million, and the company repurchased $41.0 million of stock, leaving $274.1 million in its authorization.
Knife River reported second-quarter 2024 revenue of $806.9 million, up 3% from $785.2 million, and net income of $77.9 million, up 37% from $56.8 million a year earlier. The company raised its full-year 2024 guidance to revenue of $2.8 billion to $3.0 billion and Adjusted EBITDA of $445 million to $485 million, which points to higher expected profit for shareholders, though revenue declined in the Central and Energy Services segments.
Q2 2024 revenue $806.9 million, up 3%; diluted net income per share $1.37 versus $1.00 a year earlier
Q2 2024 Adjusted EBITDA $154.3 million, up 22%; Adjusted EBITDA margin 19.1% versus 16.1%
2024 guidance raised: revenue $2.8 billion to $3.0 billion; Adjusted EBITDA $445 million to $485 million
At June 30, 2024, unrestricted cash was $15.5 million and gross debt was $693.5 million
RB Global reported second quarter 2024 results, with total revenue down 1% year-over-year to $1.1 billion while net income available to common stockholders rose 30% to $100.7 million. The company raised its full-year 2024 adjusted EBITDA outlook to $1,220 million to $1,270 million but lowered its GTV growth outlook to 0% to 2% from 1% to 4%. The board also declared a quarterly cash dividend of $0.29 per share, an increase of 7%.
Total revenue fell 1% year-over-year to $1.1 billion, while net income available to common stockholders rose 30% to $100.7 million.
Diluted EPS was $0.54, up 29%; diluted adjusted EPS was $0.94, up 15%.
Full-year 2024 adjusted EBITDA outlook raised to $1,220 million to $1,270 million from $1,200 million to $1,260 million; GTV growth outlook lowered to 0% to 2% from 1% to 4%.
Quarterly dividend of $0.29 per share is payable September 18, 2024, to shareholders of record on August 28, 2024.
Enpro reported second-quarter 2024 net sales of $271.9 million, down 1.8% from a year earlier, while GAAP income from continuing operations swung to $26.7 million from a loss of $18.6 million. The company lowered the top end of its full-year 2024 adjusted EBITDA and adjusted EPS ranges and now expects revenue to be approximately flat, which matters to shareholders because the outlook is narrower and less optimistic than before.
Net sales of $271.9 million fell 1.8%; organic sales fell 5.0%.
GAAP diluted EPS was $1.27 versus a loss of $0.89; adjusted diluted EPS rose 13.7% to $2.08.
Full-year 2024 adjusted EBITDA guidance narrowed to $260 million to $270 million from $260 million to $280 million; adjusted EPS guidance narrowed to $7.00 to $7.60 from $7.00 to $7.80.
Advanced Surface Technologies sales fell 12.2% to $88.1 million on semiconductor market conditions.
TG Therapeutics reported second-quarter 2024 total revenue of $73.5 million, up from $16.1 million a year earlier, and net income of $6.9 million compared with a net loss of $47.6 million in the same period of 2023. The company raised its full-year 2024 U.S. BRIUMVI net revenue target to $290 million to $300 million from $270 million to $290 million, and authorized a share buyback of up to $100 million funded by a new $250 million term loan that repaid its Hercules debt.
Q2 2024 total revenue was $73.5 million versus $16.1 million in Q2 2023; diluted EPS was $0.04 versus $(0.34).
Full-year 2024 U.S. BRIUMVI net revenue target raised to $290 million to $300 million from $270 million to $290 million.
$250 million term loan with Blue Owl Capital and HealthCare Royalty matures August 2, 2029; proceeds repaid Hercules debt, and the Board authorized up to $100 million in share repurchases.
Audit Committee concluded a 2021 stock-grant expense error reflects a material weakness in internal control as of December 31, 2023; a 10-K/A will follow, and the company states there are no financial changes to the 2023 annual report.
Bentley Systems reported second-quarter 2024 results, with total revenue of $330.3 million, up 11.3% from a year earlier, and net income of $72.0 million, or $0.22 per diluted share, compared with $0.15 a year earlier. The company also said Greg Bentley moved from chief executive to executive chair and Nicholas Cumins became chief executive, effective July 1, 2024.
Q2 2024 total revenues $330.3 million, up 11.3% year over year; subscriptions revenues $297.4 million, up 14.7%
Net income per diluted share $0.22 vs $0.15; Adjusted EPS $0.31 vs $0.24
Annualized recurring revenues $1,215.9 million at June 30, 2024, up from $1,105.9 million; constant currency ARR growth 11%
Effective July 1, 2024, Nicholas Cumins became chief executive officer, succeeding Greg Bentley, who became executive chair
Edgewell Personal Care named Daniel Sullivan Chief Operating Officer and Francesca Weissman as Chief Financial Officer effective December 1, 2024, and said North America president Eric O'Toole will step aside under a separation agreement effective November 15, 2024. The changes were announced alongside third-quarter fiscal 2024 results, in which the company said it raised its fiscal 2024 Adjusted EBITDA and Adjusted EPS outlook.
Daniel J. Sullivan appointed Chief Operating Officer effective August 6, 2024; he remains CFO until December 1, 2024.
Francesca Weissman becomes CFO effective December 1, 2024, succeeding Sullivan.
The company raised its fiscal 2024 Adjusted EBITDA and Adjusted EPS outlook; the filing does not state the new figures.
Avient reported second quarter 2024 sales of $849.7 million, up from $824.4 million a year earlier, and adjusted EPS of $0.76 versus $0.63, above its $0.71 guidance. The company raised its full-year 2024 adjusted EPS guidance to $2.55 to $2.70 from $2.50 to $2.65, and its adjusted EBITDA guidance to $515 million to $540 million from $510 million to $535 million.
Q2 sales were $849.7 million, up from $824.4 million, with organic sales up 5% excluding foreign exchange.
Q2 adjusted EPS was $0.76 versus $0.63 a year earlier and above the $0.71 guidance; GAAP EPS from continuing operations was $0.36 versus $0.24.
Full-year 2024 adjusted EPS guidance rose to $2.55 to $2.70 from $2.50 to $2.65.
Third quarter adjusted EPS is expected at $0.62, a 9% increase; Investor Day is set for December 4 in New York City.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.